Why the study?
Computational platforms can reduce the costs and time required to develop new medical devices and drugs, motivating the development and clinical validation of an AI-based Decision Support System to predict heart failure risk and facilitate early diagnosis.
The STRATIFYHF project aims to develop an AI-based computational platform to predict heart failure risk and progression, potentially transforming its management.
The use of a computational platform can reduce costs and time required for developing new models of medical devices and drugs. EU project STRATIFYHF is to develop and clinically validate a truly innovative AI-based Decision Support System for predicting the risk of heart failure, facilitating its early diagnosis and progression prediction that will radically change how heart failure is managed in both primary and secondary care. It is developed using state-of-the-art finite element modelling for macro simulation of fluid-structure interaction with micro modelling at the molecular level for drug interaction with the cardiac cells and using artificial intelligence. Computational platforms such as STRATIFYHF platform is novel medical tool for risk prediction of cardiac disease in a specific patient.
No takes yet. Share an insight, caveat, or question.
Nenad Filipović (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: